2946-39-6Relevant articles and documents
The supramolecular helical architecture of 8-oxoinosine and 8-oxoguanosine derivatives
Lena, Stefano,Cremonini, Mauro A.,Federiconi, Francesco,Gottarelli, Giovanni,Graziano, Carla,Laghi, Luca,Mariani, Paolo,Masiero, Stefano,Pieraccini, Silvia,Spada, Gian Piero
, p. 3441 - 3449 (2007)
The 8-oxoguanosine derivative 1 and the 8-oxoinosine derivative 2b, with appropriate substituents on their ribose moieties, form hexagonal lyotropic mesophases in hydrocarbon solvents. Small-angle X-ray scattering analysis of a film of 1 and of the mesophase of 2b, and NMR and CD spectra of isotropic solutions of 2b, indicate that in both cases the supramolecular structures adopted are continuous helices formed by a hydrogen-bond network between the heterocyclic bases. Notably, while derivative 2b, which bears large substituents on its ribose moiety, undergoes self-assembly and mesophase formation, oxoinosine 2a, with only decanoyl groups on its ribose moiety, does not. This may be ascribed to the reduced amphiphilic properties of the latter and the absence of aromatic groups.
Investigation of the action of poly(ADP-ribose)-synthesising enzymes on NAD+ analogues
Wallrodt, Sarah,Simpson, Edward L.,Marx, Andreas
, p. 495 - 501 (2017)
ADP-ribosyl transferases with diphtheria toxin homology (ARTDs) catalyse the covalent addition of ADP-ribose onto different acceptors forming mono- or poly(ADP-ribos)ylated proteins. Out of the 18 members identified, only four are known to synthesise the complex poly(ADP-ribose) biopolymer. The investigation of this posttranslational modification is important due to its involvement in cancer and other diseases. Lately, metabolic labelling approaches comprising different reporter-modified NAD+ building blocks have stimulated and enriched proteomic studies and imaging applications of ADP-ribosylation processes. Herein, we compare the substrate scope and applicability of different NAD+ analogues for the investigation of the polymer-synthesising enzymes ARTD1, ARTD2, ARTD5 and ARTD6. By varying the site and size of the NAD+ modification, suitable probes were identified for each enzyme. This report provides guidelines for choosing analogues for studying poly(ADP-ribose)-synthesising enzymes.
Coumarin-purine ribofuranoside conjugates as new agents against hepatitis c virus
Hwu, Jih Ru,Lin, Shu-Yu,Tsay, Shwu-Chen,De Clercq, Erik,Leyssen, Pieter,Neyts, Johan
, p. 2114 - 2126 (2011)
About 3% of world's population is infected by the hepatitis C virus (HCV), for which prophylactic vaccine is not available yet. Nowadays, pegylated interferon-α and ribavirin are commonly used to treat HCV; unfortunately these drugs often produce significant side effects. Upon the desperate need of anti-HCV drugs, a plan to establish a new compound library was set that included leads with high antiviral activity, good hydrophilicity, yet low toxicity. Accordingly, 26 new conjugated compounds were synthesized through the chemical coupling of various 9-(β-d-ribofuranosyl)purine-8-thiones with 3-(chloromethyl)coumarins bearing various substituents. A SCH2 unit was used to link the coumarin and the purine moieties. The three hydroxyl groups at the 2′-, 3′-, and 5′-positions were selectively protected with an acyl or acetal group in these coumarin-purine ribofuranosides. Their anti-HCV and cytostatic determination assays were performed, and the structure-activity relationship was established. Three conjugates in the family of 8-(coumarin-3′-yl)methylthio-9-(β-d-ribofuranos-1′-yl)purine possessed an appealing ability to inhibit HCV replication with EC50 between 5.5 and 6.6 μM and EC90 of 20 μM. These data in the new compound library provide clues for the future in the development of anti-HCV leads for viral eradication.
Cyclic dinucleotide analogues, pharmaceutical composition of analogues and applications of analogues and pharmaceutical composition
-
Paragraph 0380; 0381; 0382; 0383, (2020/04/17)
The invention discloses cyclic dinucleotide analogues, a pharmaceutical composition of the analogues and applications of the analogues and the pharmaceutical composition. The cyclic dinucleotide analogs (I), an isomer, prodrug, stable isotope derivative or pharmaceutically acceptable salt of the analogs have a structure shown in the specification. The cyclic dinucleotide analogs provided by the invention can be used as regulators of stimulator of interferon genes (STIG) and related signaling pathways, and can effectively treat and/or alleviate multiple types of diseases, including but not limited to malignant tumors, inflammation, autoimmune diseases and infectious diseases; and in addition, the STING regulators can also be used as vaccine adjuvants.
Synthetic method for 8-bromoadenosine
-
Paragraph 0017-0028, (2018/07/06)
The invention discloses a synthetic method for 8-bromoadenosine, belonging to the field of chemical synthesis. The product namely 8-bromoadenosine is obtained with adenosine as a raw material through8-bromo substitution. According to the invention, the usage amount of a substrate Br2 and the concentration and pH range of an acetic acid-sodium acetate buffer solution are controlled, and the usageamount of a quenching agent NaHSO3 is reduced at the same time, so process cost is comprehensively reduced, and the index of COD in wastewater is decreased; and directed at the problem of returning ofa product to a raw material due to a quenching reaction of NaHSO3, quenching time is shortened, so the yield of the product is improved.
